, Sept. 25
/PRNewswire/ -- Today, researchers presented new data showing molecular imaging agent 123I-m
IBG can help cardiologists define risk in heart failure patients. As an extension of the ADMIRE-HF trial, the ADMIRE-HFX study assessed 123I-m
IBG as a risk stratifier for arrhythmic events and cardiac death in subjects with heart failure.
The original ADMIRE-HF trial studied 961 heart failure subjects with left ventricular ejection fraction who underwent planar and SPECT 123I-mIBG myocardial imaging. Cardiac 123I-mIBG uptake was quantified as the heart/mediastinum ratio (H/M) on 4-hours anterior planar (p) images of all subjects and SPECT (s) images of 928 subjects.
Among the subjects with both H/Mp and H/Ms, 133 had cardiac events, including transplants (6), left ventricular assist devices (3), arrhythmic events (69), and cardiac deaths (56). Eight subjects with non-fatal arrhythmic events subsequently had cardiac death. A two-year cardiac and all-cause mortality in the total population were 7.8% and 11.6%
The study showed that preserved sympathetic innervations was associated with a very low risk of cardiac death over two years, and neither planar nor SPECT global 123I-mIBG quantitation yielded a significant hazard ratio for defining arrhythmic event risk.
Dr. Denis Agostini will present this study, "Predicting Cardiac and All-Cause Mortality using 123I-mIBG Myocardial Scintigraphy in Heart Failure Patients: Results from the ADMIRE-HF Extension (X) Trial" Saturday, September 25, 2010 at 12:00 p.m. in the Grand Ballroom, Salon H at the Marriot Downtown Philadelphia.
The American Society of Nuclear Cardiology (ASNC) is the leader in education, advocacy, and quality for the field of nuclear cardiology. Serving more than 5,000 individuals in over 50 countries, ASNC is the only professional association dedicated to the dynamic subspecialty of nuclear cardiology.
SOURCE American Society of Nuclear Cardiology